Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.

Institutions Share
OHSU Knight Cancer Institute (KCI), United States of America (USA) 0.35
UCSF Department of Medicine (DOM), United States of America (USA) 0.11
UCSF Helen Diller Family Comprehensive Cancer Center, United States of America (USA) 0.09
UC Santa Cruz Genomics Institute, UCSC, United States of America (USA) 0.05
University of California, Los Angeles (UCLA), United States of America (USA) 0.05
Department of Biomolecular Engineering (BME), UCSC, United States of America (USA) 0.05
Duke Department of Pathology, United States of America (USA) 0.03
Masonic Cancer Center, UMN, United States of America (USA) 0.03
OHSU Computational Biology Program, United States of America (USA) 0.03
OHSU Department of Molecular Microbiology and Immunology (MMI), United States of America (USA) 0.03
Department of Urologic Sciences, UBC, Canada 0.03
UC Davis Health, United States of America (USA) 0.03
UCLA Department of Microbiology, Immunology and Molecular Genetics (MIMG), United States of America (USA) 0.03
VA Greater Los Angeles Healthcare System, United States of America (USA) 0.02
Department of Radiation Oncology, U-M, United States of America (USA) 0.02
Rogel Cancer Center, U-M, United States of America (USA) 0.02
UCSF Department of Epidemiology and Biostatistics, United States of America (USA) 0.01
UCSF Department of Radiation Oncology, United States of America (USA) 0.01
UCSF Department of Urology, United States of America (USA) 0.01

Return